Arq Valuation

Is ARQ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ARQ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ARQ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ARQ's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ARQ?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for ARQ. This is calculated by dividing ARQ's market cap by their current preferred multiple.
What is ARQ's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$255.96m

ARQ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.5x
Enterprise Value/EBITDA	75.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ARQ's PS Ratio compare to its peers?

The above table shows the PS ratio for ARQ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.1x
DNA Ginkgo Bioworks Holdings	2.4x	12.9%	US$454.0m
VNTR.F Venator Materials	0.2x	n/a	US$487.1m
RYAM Rayonier Advanced Materials	0.3x	2.8%	US$494.2m
NTIC Northern Technologies International	1.6x	10.7%	US$126.1m
ARQ Arq	2.3x	19.8%	US$256.0m

Price-To-Sales vs Peers: ARQ is expensive based on its Price-To-Sales Ratio (2.3x) compared to the peer average (1.1x).

Price to Earnings Ratio vs Industry

How does ARQ's PE Ratio compare vs other companies in the US Chemicals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	17.8%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	17.8%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: ARQ is expensive based on its Price-To-Sales Ratio (2.3x) compared to the US Chemicals industry average (1.4x).

Price to Sales Ratio vs Fair Ratio

What is ARQ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ARQ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.4x
Fair PS Ratio	3.2x

Price-To-Sales vs Fair Ratio: ARQ is good value based on its Price-To-Sales Ratio (2.3x) compared to the estimated Fair Price-To-Sales Ratio (3.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.